Iovance Biotherapeutics, Inc.
IOVA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,145,090 | $1,911,615 | $1,017,665 | $2,928,521 |
| - Cash | $115,694 | $114,888 | $231,731 | $78,229 |
| + Debt | $58,261 | $75,862 | $85,446 | $71,531 |
| Enterprise Value | $2,087,657 | $1,872,589 | $871,380 | $2,921,823 |
| Revenue | $164,070 | $1,189 | $0 | $0 |
| % Growth | 13,699% | – | – | – |
| Gross Profit | $40,075 | -$9,566 | $0 | $0 |
| % Margin | 24.4% | -804.5% | – | – |
| EBITDA | -$351,672 | -$427,432 | -$377,743 | -$328,723 |
| % Margin | -214.3% | -35,948.9% | – | – |
| Net Income | -$372,177 | -$444,037 | -$395,893 | -$342,252 |
| % Margin | -226.8% | -37,345.4% | – | – |
| EPS Diluted | -1.28 | -1.89 | -2.49 | -2.23 |
| % Growth | 32.3% | 24.1% | -11.7% | – |
| Operating Cash Flow | -$352,977 | -$361,820 | -$292,757 | -$227,941 |
| Capital Expenditures | -$11,069 | -$22,290 | -$20,425 | -$37,574 |
| Free Cash Flow | -$364,046 | -$384,110 | -$313,182 | -$265,515 |